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Human polyomaviruses JC and BK may cause several clinical manifestations in immunocompromised hosts,
including progressive multifocal leukoencephalopathy and hemorrhagic cystitis. Molecular detection by PCR
is recognized as a sensitive and specific method for detecting human polyomaviruses in clinical samples. In this
study, a real-time PCR assay using the LightCycler platform was evaluated and compared to an “in-house”
PCR assay using a conventional detection method. A total of 122 urine specimens were tested, and human
polyomavirus was detected in 49 specimens (40%) by both conventional PCR and LightCycler PCR. The
remaining 73 specimens (60%) were found negative by both assays. For 46 of the 49 positive specimens,
LightCycler PCR and conventional PCR identified the same polyomavirus type. These samples included 30
samples with JC virus (JCV), 14 samples with BK virus (BKV), and 2 samples in which both viruses were
detected. In the remaining three samples, both JCV and BKV were detected by the conventional assay, but only
JCV was detected by the LightCycler assay. The results of this study show that the LightCycler PCR assay
displays sensitivity and specificity similar to those of a conventional PCR assay. These data, combined with its
rapid turnaround time for results and decreased hands-on time, make the LightCycler PCR assay highly
suitable for the rapid detection and differentiation of JCV and BKV in the clinical laboratory.
Human polyomaviruses JC and BK are ubiquitous in the
population (8). Primary infections with these viruses are usu-
ally asymptomatic and may result in transient viruria. Follow-
ing primary infection, JC virus (JCV) and BK virus (BKV)
both establish latency in renal tissues and in B lymphocytes
(20; G. Lecatsas, B. D. Schoub, A. R. Rabson, and M. Joffe,
Letter, Lancet 2:907–908, 1976). Polyomavirus-related disease
is largely associated with immunological impairment, and rapid
detection and differentiation of the etiological agent in immu-
nocompromised patients are important to assist with clinical
management. JCV is the causative agent of the neurological
disease progressive multifocal leukoencephalopathy, which oc-
curs primarily in AIDS patients (16, 19), whereas BKV-asso-
ciated disease includes hemorrhagic cystitis, ureteral stenosis,
and other urinary tract disease, which are most commonly
found in transplant patients undergoing immunosuppressive
therapy (5, 9).
Traditional methods for detecting and identifying polyoma-
viruses include serologic methods, virus isolation by cell cul-
turing, and electron microscopy (15, 17, 21). Recently, several
studies have shown PCR to be an effective tool for detecting
polyomaviruses in a range of clinical samples (4, 7, 11); as a
result, PCR is now emerging as the “gold standard” for poly-
omavirus detection. However, the routine implementation of
nucleic acid amplification techniques in the clinical laboratory
has limitations, because of concerns of amplicon carryover
contamination and technically cumbersome PCR product de-
tection methods (14, 24). Real-time PCR instrumentation is
the latest advance in nucleic acid amplification and detection
technology that overcomes many of these limitations. We de-
veloped a real-time PCR assay for the detection and charac-
terization of polyomaviruses using the LightCycler instrument
(Roche Molecular Biochemicals). This technology applies flu-
orescence resonance energy transfer (FRET) in the continuous
monitoring of amplicon development by use of two fluoro-
phore-labeled hybridization probes (25). Using the Light-
Cycler PCR (LC-PCR) assay, we examined 122 urine speci-
mens for the presence of polyomaviruses and characterized the
viruses when present by melting curve analysis. The results
were compared with the results obtained by a conventional
PCR assay developed in our laboratory, which used solid-phase
hybridization and a colorimetric detection system.
MATERIALS AND METHODS
Specimens and nucleic acid extraction. To ensure that a diverse sample pop-
ulation was tested in this study, we included urine specimens (n  122) that were
obtained from a general hospital population and that were submitted to the
diagnostic laboratory of the Queensland Health Pathology Service for the rou-
tine investigation of microorganisms. Patient groups represented included (i)
sexual health clinic (n  22), (ii) pediatric clinic (n  26), (iii) antenatal clinic
(n  20), (iv) indigenous health clinic (n  10), (v) general adult medical wards
(n  20), and (vi) immunocompromised (n  24). Nucleic acid was extracted
from 0.2 ml of each specimen with a QIAamp DNA blood mini kit (Qiagen)
according to the manufacturer’s protocol. This procedure has been shown to be
suitable for the extraction of viral DNA from urine specimens because of the
high DNA yield and the removal of PCR inhibitors (12). DNA was eluted from
the column with 50 l of PCR-grade water (Baxter water for irrigation).
LC-PCR. The LightCycler instrument provides a platform for the amplifica-
tion of target nucleic acid and monitors the development of amplification reac-
tion products by fluorescence after the annealing step in each cycle. Primers
PoL1s and PoL2as used in the LC-PCR target a sequence of the VP2 gene that
is conserved between JCV and BKV, producing a 131-bp product during the
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reaction (Table 1). The continuous monitoring of amplicon development was
based on the FRET principle and was performed using two adjacent hybridiza-
tion probes. One probe, PoLP1 (probe 1), was labeled with a donor fluorescein
fluorophore at the 3 end, and a second probe, PoLP2 (probe 2), was labeled with
an acceptor fluorophore, LC-Red 640, at the 5 end. Probe 2 was also labeled
with a 3 phosphorylated residue to prevent extension of the probe by Taq DNA
polymerase during the reaction (Table 1).
A LightCycler FastStart DNA master hybridization probes kit (Roche Molec-
ular Biochemicals) was used as the basis for the reaction mixture in the LC-PCR
assay; a 20-l volume was used in each reaction capillary. Briefly, capillaries were
loaded with 2 l of LightCycler FastStart DNA master hybridization probes
reagent (10; Roche Molecular Biochemicals; reagent 1), 2.4 l of MgCl2 stock
solution (25 mM; Roche Molecular Biochemicals; reagent 2), 2 pmol of sense
primer, 8 pmol of antisense primer, 4 pmol of each probe, and 5 l of target
DNA. Each mixture was made up to 20 l using sterile PCR-grade water (Roche
Molecular Biochemicals; reagent 3). Besides a positive control, each test run
included three no-target controls consisting of 15 l of reaction mixture and 5 l
of PCR-grade water. Reaction capillaries were capped, centrifuged, and placed
into the carousel of the LightCycler instrument. The LC-PCR protocol included
the following parameters: an initial 10 min of incubation at 95°C for FastStart
Taq DNA polymerase activation followed by 55 cycles of denaturation at 95°C
for 10 s, annealing at 55°C for 10 s, and extension at 72°C for 20 s. The data were
obtained during the annealing period in the “single” mode with the channel
setting F2/F1. The fluorescence settings were set to 1 for F1 gain and 15 for F2
gain. F3 gain was not used in the analysis of the data.
LightCycler melting curve analysis for JCV and BKV differentiation. The
LightCycler hybridization probes were designed for JCV, and genomic sequence
differences between JCV and BKV were detected by melting curve analysis.
Essentially both hybridization probes had 100% homology to the JCV sequence,
but each probe had a single base mismatch compared to the BKV sequence.
Melting curve analysis was performed following PCR amplification using Light-
Cycler software. Briefly, the analysis was commenced at 55°C, and the temper-
ature was raised to 95°C at a rate of 0.1°C/s. The difference between the sequence
of the BKV PCR product and the probes resulted in a shift in melting temper-
ature (5°C) compared to the results for the JCV sequence (Fig. 1).
Conventional PCR amplification. The conventional PCR was performed using
primers PoE1s and PoE2as, which are homologous to a region of sequence of the
VP1 gene of JCV and BKV, resulting in a 434-bp product (Table 1) (D. M.
Whiley et al., unpublished data). The assay was done with a 50-l reaction
volume containing 2 U of Platinum Taq DNA polymerase (Life Technology); 5
l of 10 PCR buffer (Life Technology); 2.5 mM MgCl2 solution (Life Tech-
nology); 10 pmol of each primer; 200 M (each) dATP, dGTP, and dCTP
(Promega); 400 M dUTP (Promega); 0.1 nmol of digoxigenin-11-dUTP (Roche
Molecular Biochemicals); and 5 l of specimen extract or controls. The reaction
volume was adjusted to 50 l with PCR-grade water. PCR amplification was
performed with a Perkin-Elmer 2400 thermal cycler (Applied Biosystems) using
the following conditions: initial denaturation of DNA and activation of Platinum
Taq DNA polymerase at 94°C for 2 min followed by 45 cycles at 94°C for 20 s,
55°C for 20 s, and 72°C for 20 s. These steps were followed by an additional
primer extension step of 7 min at 72°C.
Detection of amplification products. An enzyme-linked amplicon hybridiza-
tion assay (ELAHA) developed in our laboratory was used for amplicon detec-
tion (18). This method included two hybridization reactions for each sample, one
using a JCV-specific probe, PoEJP2, and one using a second probe, PoEBP1,
which was BKV specific. Both probes were labeled at the 5 terminus with biotin
during manufacture (Table 1). Following amplification, 10 l of reaction mixture
was added to each of two reaction tubes (200 l) containing 10 ng of either
probe. Forty microliters of 1 SSC (0.15 M NaCl plus 0.015 M sodium citrate)
was added to each tube, giving a final reaction volume of 50 l. The tubes were
placed into a thermal cycler (Applied Biosystems) and kept at 94°C for 5 min to
denature the amplicon, followed by rapid cooling to 4°C. Following denaturation,
the contents of the tubes were transferred to streptavidin-coated wells (Lab-
systems) and incubated for 20 min at 37°C. The wells were washed four times
with 1 SSC. Antidigoxigenin-peroxidase conjugate solution (Roche Diagnos-
tics) was prepared by diluting the conjugate in phosphate-buffered saline (pH
7.2) to a final concentration of 150 mU/ml. Fifty microliters of diluted conjugate
was added to each well and incubated for 20 min at 37°C. The wells were washed
four times with 1 phosphate-buffered saline containing 0.5% Tween 20. Finally,
100 l of tetramethylbenzidine substrate (Elisa Systems; contains tetramethyl-
benzidine at 2.08 mmol per liter; pH 3.3) was added to each well and incubated
at room temperature for 10 min. The reaction was stopped by the addition of 100
l of 1 M HCl to each well. The absorbance was recorded using a plate spec-
trophotometer (Murex Diagnostics) at a wavelength of 450 nm, with 690 nm as
a reference. A positive result was indicated by an absorbance of 0.2 or greater.
Determination of LC-PCR assay sensitivity relative to that of PCR-ELAHA.
JCV and BKV DNA specimens previously extracted from a urine specimen that
tested positive for these viruses by conventional PCR were diluted in serial
10-fold dilutions ranging from 101 to 107 in PCR-grade water. These dilutions
were tested with both the LC-PCR assay and the conventional PCR-ELAHA
using the conditions described above. The detection limit of each assay was
determined as the lowest dilution returning a positive reaction.
FIG. 1. LightCycler melting curve analysis for the differentiation of
JCV and BKV.
TABLE 1. Primer and probe sequences used in the detection and characterization of JCV and BKV
Assay Target Primer orprobe
Amplicon size
(bp) Sequence (5-3)
LC-PCR VP2 gene Primer: PoL1s 131 CACTTTTGGGGGACCTAGT
Primer: PoL2as CTCTACAGTAGCAAGGGATGC
Probe 1: PoLP1 TCTGAGGCTGCTGCTGCCACAGGATTTT-fluorescein
Probe 2: PoLP2 LC-Red 640-AGTAGCTGAAATTGCTGCTGGAGAGGCTGCT-phosphate
PCR-ELAHA VP1 gene Primer: PoE1s 434 GGAGGAGTAGAAGTTCTAGAA
Primer: PoE2as TCTGGGTACTTTGTYCTGTA
Probe 1: PoEBP1 Biotinyl-GCTTAACCTTCATGCAGGGTCACA
Probe 2: PoEJP2 Biotinyl-GATGAATGTGCACTCTAATGGTCA
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DNA sequencing. DNA sequencing of amplification products was performed
using an ABI Prism dye terminator cycle sequencing kit (Applied Biosystems).
Essentially, PCR products were electrophoresed through a 1% agarose gel (Sig-
ma). The polyomavirus VP1-specific amplification product was excised and pu-
rified using a QIAquick gel extraction kit (Qiagen). For the sequencing reaction,
a 20-l reaction mixture was used, containing 4 l of ABI Prism terminator ready
reaction mix (Applied Biosystems), 1 l of VP1 sense primer (2 pmol/l), 10 l
of PCR-grade water, and 5 l of purified amplicon. The reaction mixture was
placed into a Perkin-Elmer 2400 thermal cycler for 35 cycles at 94°C for 30 s,
50°C for 15 s, and 60°C for 4 min and a final hold at 4°C. An ethanol precipitation
step was performed according to the protocol described by the kit manufacturer
(Applied Biosystems). Samples were analyzed on an ABI 377 DNA sequencer
(Applied Biosystems).
RESULTS
Human polyomavirus DNA was detected by both the LC-
PCR assay and the PCR-ELAHA in 49 (40.2%) of the 122
urine specimens tested. Negative results were obtained for 73
specimens. The LC-PCR-positive specimens were further in-
vestigated by melting curve analysis to determine the polyoma-
virus type present (JCV or BKV).
In the 49 polyomavirus-positive samples, a single virus type
was detected in 44 specimens by both the LC-PCR assay and
the PCR-ELAHA. The LC-PCR detected JCV in 33 speci-
mens and BKV in 14 specimens, with an additional 2 speci-
mens being positive for both JCV and BKV. In these two
specimens, both viruses were detected by both assays, whereas
the PCR-ELAHA detected both viruses in 3 of the 49 speci-
mens in which the LC-PCR detected JCV alone. In all, the
LC-PCR and PCR-ELAHA detected JCV DNA in 35 speci-
mens (28.7%), the LC-PCR detected BKV DNA in 16 speci-
mens (13.1%) (Table 2), and the PCR-ELAHA detected BKV
DNA in 19 specimens (15.6%). Further examination of results
in relation to specimen population showed that the positivity
rates for both JCV and BKV were lowest in the pediatric
population (11.5 and 0%, respectively), whereas the positivity
rates were highest in samples from immunocompromised sub-
jects (45.8% for JCV and 37.5% for BKV) (Table 2).
In the LC-PCR, the threshold cycle (CT) was determined as
the cycle number at which the sample quantification curve
became exponential. The CT values ranged from 21 to 40 cycles
for JCV-positive specimens and from 15 to 39 cycles for BKV-
positive samples (Fig. 2). No significant difference was ob-
served for the two sample populations, including those positive
for both viruses.
Testing of 10-fold serial dilutions of BKV and JCV DNAs
showed that the LC-PCR could detect dilutions equal to or less
than 104, whereas the PCR-ELAHA was able to detect dilu-
tions equal to or less than 105. This represented a 10-fold
difference in relative sensitivity between the two assays, with
the PCR-ELAHA proving the more sensitive.
Probes designed to detect nucleotide polymorphisms in two
base pairs of the BKV LC-PCR product correctly differenti-
ated JCV from BKV in all LC-PCR-positive specimens by
melting curve analysis. The melting temperatures for all JCV
and BKV amplification products were 75 and 70°C, respec-
tively, consistent with theoretical melting temperatures.
JCV amplification products obtained in the PCR-ELAHA
were sequenced, and the JCV subtypes present were identified
as 1A, 1B, 2A, 2B, 2C, and 4. The LC-PCR was able to detect
each of these six JCV subtypes in the sample population. Melt-
ing curve analysis of the LC-PCR amplification product for
each JCV subtype produced identical melting temperatures
(75°C).
DISCUSSION
The LightCycler is a newly developed, commercially avail-
able system designed to decrease the time of the PCR by
monitoring the amplification of target sequences in real time
by FRET analysis. This technology represents a significant
breakthrough in PCR amplification and amplicon detection
FIG. 2. Detection of JCV and BKV in urine by LC-PCR. The
diagram shows the CT for positive polyomavirus samples. Negative
samples did not cross the threshold during the 55 PCR cycles.
TABLE 2. Distribution of JCV and BKV in urine specimens tested
by LC-PCR and classified by patient type (n  122)
Patient group
No. of
patients
tested
Distributiona of:
Total %
positiveJCV BKV
No. % No. %
Sexual health clinic 22 6 27.2 1 4.5 31.7
Pediatric clinic 26 3 11.5 0 0 11.5
Antenatal clinic 20 4 20.0 3 15.0 35.0
Indigenous health clinic 10 3 33.3 0 0 33.3
General adult medical wards 20 8 40.0 3 15.0 55.0
Immunocompromised 24 11b 45.8 9b 37.5 83.3
Total 122 35 16 40.2
a Positive results.
b Two samples were positive for both JCV and BKV.
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compared to the open and contamination-susceptible methods
used in conventional PCR, and its benefits over conventional
PCR have been documented (13, 14, 22, 23). For our study,
this technology offered some significant benefits in diagnosing
JCV and BKV infections. The LC-PCR assay could generate
results within 1.5 h of receipt of the specimen into the labora-
tory, significantly faster than the 5 to 6 h required for PCR-
ELAHA, and hands-on time was significantly reduced because
of the elimination of the need for the additional detection step
required by PCR-ELAHA.
Because of the frequency of infection and the risk of dis-
seminated disease in the immunologically compromised host,
rapid laboratory detection of polyomavirus has become an
important issue in diagnostic virology; in addition, identifica-
tion of the polyomavirus present has significance for patient
management. Traditional methods of diagnosing polyomavirus
infections, such as isolation or serologic analysis, are not widely
practiced in the routine diagnostic laboratory because of tech-
nical limitations or the lack of commercial reagents. Nucleic
acid amplification techniques, particularly PCR, have demon-
strated superior sensitivity compared to all other diagnostic
methods for the detection of polyomaviruses, but the routine
implementation of PCR in the clinical laboratory has been
impeded by problems of amplicon carryover contamina-
tion and time-consuming amplicon detection techniques (14,
24).
In this study, the LC-PCR detected JCV in samples from all
patient groups, with the lowest prevalence in the pediatric
population and the highest in the immunocompromised pop-
ulation. The high rate of polyomavirus reactivation in immu-
nocompromised patients is well documented, particularly in
transplant recipients and AIDS patients (5, 6, 10), which
formed the majority of our sample group. Similarly, the prev-
alence of BKV was highest in our samples from immunocom-
promised subjects, but this virus was not detected in the pedi-
atric and indigenous health clinic samples. The low prevalence
of JCV and BKV in our pediatric population was not surpris-
ing, as the subjects in this group were predominantly younger
than 4 years, when community exposure to these viruses is
limited. In contrast, the low prevalence of BKV in samples
from the indigenous health clinic group was probably due to
the small number of samples tested, and conclusions about
these results are premature. In the antenatal clinic and general
adult medical ward sample populations, both viruses were de-
tected at relatively high frequencies, consistent with previous
reports of polyomavirus reactivation in pregnant women and in
older patients (2, 3).
These results show that the LC-PCR used in this study
allows the accurate detection and characterization of polyoma-
viruses in urine specimens from a diverse patient population.
The results of this assay were in complete agreement with the
results obtained for the detection of polyomaviruses by the
PCR-ELAHA, showing that the LC-PCR is a suitable alterna-
tive to conventional PCR. However, we did establish a differ-
ence in the limit of detection between the two assays. In an
effort to resolve this anomaly, various parameters of the LC-
PCR assay were reexamined and optimized. It was found that
asymmetric addition of the primers produced optimal results.
The addition of the antisense primer in a fourfold excess re-
sulted in a significant increase in fluorescence emitted during
the reaction. This procedure also improved the differentiation
of amplicon DNA during melting curve analysis. Testing a
dilution series of positive DNA samples showed that the LC-
PCR remained less sensitive than the conventional PCR by a
factor of 10. This result was somewhat surprising but might
represent a limitation in the use of hybridization probes for
FRET detection of amplicons. The difference in sensitivity
could also have been due to thermodynamic differences inher-
ent in the primers and/or probes used in the assay. However,
the primer sets for the LC-PCR and the conventional PCR
were selected for their similar melting temperatures and thus
should have had similar thermodynamic characteristics. Alter-
natively, differences in sensitivity might have been related to
the secondary structure of the target DNA at the primer or
probe binding sites.
In characterizing the polyomavirus type present, the LC-
PCR failed to identify BKV in three of the five specimens in
which both viruses were detected by PCR-ELAHA. This result
may have been due to differences in PCR sensitivity between
the assays or to competition for hybridization probes because
of differences in the relative load of each virus in the clinical
specimen. In the three samples in question, the LC-PCR did
detect JCV, further suggesting that perhaps JCV was detected
in preference to BKV as a result of the hybridization probes
having greater sequence homology and therefore greater af-
finity for the JCV amplicon. The extent to which this limitation
applies would depend on the relative loads of JCV and BKV in
the sample. This means that the chances of identifying a dual
infection would be greatly reduced in circumstances where the
concentration of JCV DNA is in significant excess over that of
BKV DNA.
The human polyomavirus genome displays a great deal of
sequence variation, not only between JCV and BKV but also
within the various subtypes of JCV (1). This fact presents
considerable difficulties in designing primers and probes for
the detection of JCV and BKV by LC-PCR. In this study, we
identified conserved binding sites and evaluated PCR primers
and hybridization probes for application in a sensitive and
specific LC-PCR assay for JCV and BKV. The LC-PCR and
PCR-ELAHA targeted different gene sequences on the human
polyomavirus genome, yet the results showed good agreement,
thereby adding further confidence to the specificity of the as-
say. Also, the LC-PCR primer and probe target binding sites
for JCV proved to be highly conserved, as demonstrated by the
ability of the assay to detect a range of JCV subtypes (1A, 1B,
2A, 2B, 2C, and 4). In addition, all BKV and JCV isolates gave
the expected melting temperatures on melting curve analysis.
In recent years, many PCR protocols for the detection of
infectious agents in the clinical diagnostic laboratory have been
described. The advent of real-time PCR using the LightCycler
has created new potential to expand the use of PCR in disease
diagnosis. The sensitivity and specificity of our human poly-
omavirus LC-PCR assay, combined with the added benefits of
real-time detection, make it particularly suitable for the detec-
tion and differentiation of JCV and BKV in a clinical labora-
tory. Our aims are to implement the polyomavirus LC-PCR as
a routine diagnostic assay and to further expand the use of
LightCycler technology as a test platform in the diagnostic
laboratory.
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